10X Genomics Inc (TXG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
10X Genomics Inc stock (TXG) is currently trading at $20.91. 10X Genomics Inc PS ratio (Price-to-Sales) is 3.94. Analyst consensus price target for TXG is $20.14. WallStSmart rates TXG as Sell.
- TXG PE ratio analysis and historical PE chart
- TXG PS ratio (Price-to-Sales) history and trend
- TXG intrinsic value — DCF, Graham Number, EPV models
- TXG stock price prediction 2025 2026 2027 2028 2029 2030
- TXG fair value vs current price
- TXG insider transactions and insider buying
- Is TXG undervalued or overvalued?
- 10X Genomics Inc financial analysis — revenue, earnings, cash flow
- TXG Piotroski F-Score and Altman Z-Score
- TXG analyst price target and Smart Rating
10X Genomics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
10X Genomics Inc (TXG) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
10X Genomics Inc (TXG) Key Strengths (2)
107.98% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
10X Genomics Inc (TXG) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 0.60% annually
Revenue is fairly priced at 3.94x sales
Fairly priced relative to book value
Supporting Valuation Data
10X Genomics Inc (TXG) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.94), Price/Book (2.95) suggest expensive pricing. Growth concerns include Revenue Growth at 0.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -5.78%, Operating Margin at -9.42%, Profit Margin at -6.77%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -5.78% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TXG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TXG's Price-to-Sales ratio of 3.94x trades at a deep discount to its historical average of 18.42x (24th percentile). The current valuation is 94% below its historical high of 64.62x set in Apr 2021, and 142% above its historical low of 1.63x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~1.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for 10X Genomics Inc (TXG) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
10X Genomics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 643M with 1% growth year-over-year. The company is currently unprofitable, posting a -6.8% profit margin.
Key Findings
Generating 39M in free cash flow and 41M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -6.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 2.21, so expect amplified moves relative to the broader market.
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact 10X Genomics Inc.
Bottom Line
10X Genomics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About 10X Genomics Inc(TXG)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.